Epithelial Ova Cancer Metastases to the Brain

Epithelial Ovarian Cancer Metastasizing to the Brain: A Late Manifestation of the Disease With an Increasing Incidence

By Desiree F. Kolomainen, James M.G. Larkin, Mohammad Badran, Roger P. A’Hern, D. Michael King, Cyril Fisher, Jane E. Bridges, Peter R. Blake, Desmond P.J. Barton, John H. Shepherd, Stanley B. Kaye, Martin E. Gore

From the Gynaecology Unit, Royal Marsden Hospital, London, United Kingdom.

Address reprint requests to Martin E. Gore, PhD, The Royal Marsden Hospital, 203 Fulham Rd, London, SW3 6JJ, United Kingdom; email: Martin.Gore@rmh.nthames.nhs.uk.

PURPOSE: We present the Royal Marsden Hospital experience of cerebral metastases from primary epithelial ovarian carcinoma (EOC) over the last 20 years and examine the evidence for an increasing incidence of EOC metastasizing to this site.

PATIENTS AND METHODS: A total of 3,690 women with EOC were seen at the Royal Marsden Hospital from 1980 to 2000. Eighteen of these patients developed cerebral metastases.

RESULTS: Median age at diagnosis of EOC was 52 years (range, 39 to 67). All patients received at least one line of platinum-based chemotherapy; 56% (10 of 18) received more than one line of treatment; 17% (three of 18), two lines; 11% (two of 18), three lines; and 28% (five of 18), four lines. The median treatment interval between each line of chemotherapy was 12, 18, and 4 months. The median interval between diagnosis and CNS relapse was 46 months (range, 12 to 113), in comparison with 5 and 7.5 months for hematogenous relapse in lung or liver, respectively (P < .001). The incidence of CNS metastases in our population from 1980 to 1984 was 0.2%; from 1985 to 1989, 0%; from 1990 to 1994, 0.3%; and from 1995 to 1999, 1.3% (P < .001).

An analysis of data from the literature also suggests that the incidence of cerebral metastases from EOC has increased over time.

CONCLUSION: CNS metastases in EOC are a rare and late manifestation of the disease, occurring in patients with a prolonged survival caused by repeated chemosensitive relapses. An analysis of our data and the data from the literature suggests that the incidence of metastasis at this site in patients with EOC is increasing.

Journal of Clinical Oncology, Vol 20, Issue 4 (February), 2002: 982-986 © 2002 American Society for Clinical Oncology

Remember we are NOT Doctors and have NO medical training.

This site is like an Encyclopedia - there are many pages, many links on many topics.

Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.